Last reviewed · How we verify
Combination therapy
Unknown - insufficient information provided to determine the specific mechanism of this combination therapy.
At a glance
| Generic name | Combination therapy |
|---|---|
| Also known as | Maciten Tab. 10mg, Atorvastatin, Quinapril, Apixaban and clopidogrel combination therapy, Pomalyst |
| Sponsor | Gachon University Gil Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This entry refers to a combination therapy from Gachon University Gil Medical Center without specification of which drugs are combined or their mechanisms. Combination therapies typically work through synergistic or complementary pathways, but the exact mechanism cannot be determined without knowing the constituent agents.
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Effects of Percutaneous Electrical Stimulation in Patients With Chronic Supraspinatus Tendinopathy (NA)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination therapy CI brief — competitive landscape report
- Combination therapy updates RSS · CI watch RSS
- Gachon University Gil Medical Center portfolio CI